ANIP Quote, Financials, Valuation and Earnings

Allogene Therapeutics has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of -295454.55%. ANI Pharmaceuticals's return on equity of -1.54% beat Allogene Therapeutics's return on equity of -52.73%.

ANI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 47.34%. On the other hand Allogene Therapeutics has an analysts' consensus of -- which suggests that it could grow by 383.51%. Given that Allogene Therapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.112% less volatile than S&P 500. In comparison Allogene Therapeutics has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.265%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Allogene Therapeutics pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Allogene Therapeutics quarterly revenues of $22K. ANI Pharmaceuticals's net income of -$24.2M is higher than Allogene Therapeutics's net income of -$66.3M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 53.21x while Allogene Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.86x versus 3,959.29x for Allogene Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of --. ANI Pharmaceuticals's return on equity of -1.54% beat Armata Pharmaceuticals's return on equity of --.

ANI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 47.34%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 258.97%. Given that Armata Pharmaceuticals has higher upside potential than ANI Pharmaceuticals, analysts believe Armata Pharmaceuticals is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.112% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.301%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Armata Pharmaceuticals quarterly revenues of --. ANI Pharmaceuticals's net income of -$24.2M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 53.21x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.86x versus 706.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of 18.02%. ANI Pharmaceuticals's return on equity of -1.54% beat Protalix BioTherapeutics's return on equity of -29.54%.

ANI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 47.34%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 695.46%. Given that Protalix BioTherapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.112% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Protalix BioTherapeutics quarterly revenues of $18M. ANI Pharmaceuticals's net income of -$24.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 53.21x while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.86x versus 3.03x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Windtree Therapeutics has a net margin of -16.29% compared to ANI Pharmaceuticals's net margin of --. ANI Pharmaceuticals's return on equity of -1.54% beat Windtree Therapeutics's return on equity of --.

ANI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 47.34%. On the other hand Windtree Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1976.54%. Given that Windtree Therapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Windtree Therapeutics is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.112% less volatile than S&P 500. In comparison Windtree Therapeutics has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.975%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays 8.65% of its earnings as a dividend. Windtree Therapeutics pays out -- of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $148.3M, which are larger than Windtree Therapeutics quarterly revenues of --. ANI Pharmaceuticals's net income of -$24.2M is lower than Windtree Therapeutics's net income of -$2.7M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 53.21x while Windtree Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.86x versus 0.26x for Windtree Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.